WO2005002512A3 - Immunotherapeutic vaccine strategy - Google Patents

Immunotherapeutic vaccine strategy Download PDF

Info

Publication number
WO2005002512A3
WO2005002512A3 PCT/US2004/018812 US2004018812W WO2005002512A3 WO 2005002512 A3 WO2005002512 A3 WO 2005002512A3 US 2004018812 W US2004018812 W US 2004018812W WO 2005002512 A3 WO2005002512 A3 WO 2005002512A3
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
domain
pathogen
epitope tag
molecule encoding
Prior art date
Application number
PCT/US2004/018812
Other languages
French (fr)
Other versions
WO2005002512A2 (en
Inventor
Robert C Rose
Original Assignee
Univ Rochester
Robert C Rose
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester, Robert C Rose filed Critical Univ Rochester
Publication of WO2005002512A2 publication Critical patent/WO2005002512A2/en
Publication of WO2005002512A3 publication Critical patent/WO2005002512A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to a fusion protein which comprises an epitope tag, a protein translocation domain, a ubiquitin domain, and a pathogen derived immunogen. The epitope tag, the protein translocation domain, the ubiquitin domain, and the pathogen derived immunogen are directly or indirectly coupled together. Alternatively, the present invention is directed to a nucleic acid construct encoding a fusion protein where the nucleic acid construct comprises a nucleic acid molecule encoding an epitope tag, a nucleic acid molecule encoding a protein translocation domain, a nucleic acid molecule encoding a ubiquitin domain, and a nucleic acid molecule encoding a pathogen derived immunogen. The nucleic acid molecules encoding the epitope tag, the protein translocation domain, the ubiquitin domain, and the pathogen derived immunogen are directly or indirectly coupled together. Methods of vaccinating a subject against a pathogen by administering the fusion protein or the nucleic acid construct to the subject under conditions effective to vaccinate the subject against the pathogen are also disclosed.
PCT/US2004/018812 2003-06-19 2004-06-14 Immunotherapeutic vaccine strategy WO2005002512A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47981503P 2003-06-19 2003-06-19
US60/479,815 2003-06-19

Publications (2)

Publication Number Publication Date
WO2005002512A2 WO2005002512A2 (en) 2005-01-13
WO2005002512A3 true WO2005002512A3 (en) 2005-04-14

Family

ID=33563805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/018812 WO2005002512A2 (en) 2003-06-19 2004-06-14 Immunotherapeutic vaccine strategy

Country Status (1)

Country Link
WO (1) WO2005002512A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614506A (en) * 2012-03-05 2012-08-01 北京工业大学 Recombinant HPV16L2 protein vaccine and preparation method thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4252769A3 (en) 2013-07-09 2023-11-29 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
CN108779171B (en) 2015-11-24 2022-07-05 安尼艾克松股份有限公司 FAB fragment of anti-complement factor C1Q and application thereof
WO2019140136A1 (en) * 2018-01-10 2019-07-18 University Of Washington Malarial vaccination methods and regimens

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091575A1 (en) * 1998-02-19 2003-05-15 Kenten John H. Ubiquitin fusion-based vaccine system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030091575A1 (en) * 1998-02-19 2003-05-15 Kenten John H. Ubiquitin fusion-based vaccine system

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SCHWARZE ET AL.: "In vivo protein transduction: Delivery of a biologically active protein into the mouse", SCIENCE, vol. 285, 3 September 1999 (1999-09-03), pages 1569 - 1572, XP002936155 *
TOBERY ET AL.: "Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen", THE JOURNAL OF IMMUNOLOGY, vol. 162, 1999, pages 639 - 642, XP002938798 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102614506A (en) * 2012-03-05 2012-08-01 北京工业大学 Recombinant HPV16L2 protein vaccine and preparation method thereof
CN102614506B (en) * 2012-03-05 2013-09-25 北京工业大学 Recombinant HPV16L2 protein vaccine and preparation method thereof

Also Published As

Publication number Publication date
WO2005002512A2 (en) 2005-01-13

Similar Documents

Publication Publication Date Title
WO2002080851A3 (en) Chimeric vaccines
WO2002092836A3 (en) Nucleic acid sequence encoding ovarian antigen, ca125, and uses thereof
WO2005066204A3 (en) Neutralizing epitope-based growth enhancing vaccine
DK1373301T3 (en) Reduction of the immunogenicity of fusion proteins
CY1109683T1 (en) ANTIGENS OF STREPTOCOCCUS PYOGENES
WO2003011899A3 (en) Antigenic polypeptides
WO2002069232A3 (en) Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity
WO2002021141A3 (en) Methods and compositions for diseases associated with amyloidosis
AU2002242016A1 (en) Nucleic acid derived vaccine that encodes an antigen linked to a polypeptide that promotes antigen presentation
WO2006042333A3 (en) Prediction and assessment of immunogenicity
WO2002072036A3 (en) Compositions and methods comprising west nile virus polypeptides
WO2000076540A3 (en) Streptococcus pneumoniae proteins and vaccines
WO2000073430A3 (en) Vaccines against conformation-dependent antigens and against antigens that are not or are not only proteins or peptides
DE60120621D1 (en) Lawsonia intracellular vaccine
DE60037900D1 (en) CHLAMYDIA ANTIGENS AND CORRESPONDING DNA FRAGMENTS AND ITS USES
WO2009025300A1 (en) Peptide capable of binding to immunoglobulin
AU2001281145A1 (en) Recombinant constructs of borrelia burgdorferi
WO2005002512A3 (en) Immunotherapeutic vaccine strategy
WO2003095480A3 (en) Brachyspira hyodysenteriae vaccine
WO2004020609A3 (en) Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
WO2005026200A3 (en) Lawsonia intracellularis subunit vaccine
WO2004007726A3 (en) Brachyspira hyodysenteriae vaccine
WO2003064609A3 (en) Targeted immunogens
WO2006037807A3 (en) Identification of regions of apical membrane antigen 1 of apicomplexan parasites suitable for targeting by vaccines and drugs by derivation and analysis of the three-dimensional structure
WO2005048918A3 (en) Anthrax vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase